Purpose of the development: The biosensor is intended for the determination of trace amounts of cytotoxic factors in human serum.

Recommended application field: The development can be used in the institutions of the Ministry of Health of Ukraine.

The development stage readiness: Pre-production model is made

Description of the development:
()
A highly sensitive cellular biosensor has been developed, which makes it possible to record the appearance in the patient's body of low concentrations (which are difficult to detect by analytical methods) of cytotoxic compounds. The appearance of these cytotoxic compounds in the body triggers a cascade of immunological reactions that lead to the formation of pathologies, in particular myasthenia. The principle of the diagnostic method is based on the fact that cytotoxic compounds interact with the cellular biosensor and lead to a change in its characteristics. The results are processed according to the developed program, and on the basis of this it is concluded that there is an autoimmune pathology and a stage of its development. Testing time takes from 30 to 60 minutes. For analysis, 50 l of patient serum is required.

Information about newness of the development:
there are Ukrainian patents -- 1 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Licence's sale
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua